148 related articles for article (PubMed ID: 29166791)
1. Evaluation of WO2017098421: GSK's benzothiazine compounds as CD73 inhibitor filings.
Gong YP; Wan RZ; Liu ZP
Expert Opin Ther Pat; 2018 Feb; 28(2):167-171. PubMed ID: 29166791
[TBL] [Abstract][Full Text] [Related]
2. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
Allard B; Turcotte M; Stagg J
Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
[TBL] [Abstract][Full Text] [Related]
3. Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73.
Beatty JW; Lindsey EA; Thomas-Tran R; Debien L; Mandal D; Jeffrey JL; Tran AT; Fournier J; Jacob SD; Yan X; Drew SL; Ginn E; Chen A; Pham AT; Zhao S; Jin L; Young SW; Walker NP; Leleti MR; Moschütz S; Sträter N; Powers JP; Lawson KV
J Med Chem; 2020 Apr; 63(8):3935-3955. PubMed ID: 32212732
[TBL] [Abstract][Full Text] [Related]
4. Role of CD73 in Disease: Promising Prognostic Indicator and Therapeutic Target.
Yang J; Liao X; Yu J; Zhou P
Curr Med Chem; 2018; 25(19):2260-2271. PubMed ID: 29345574
[TBL] [Abstract][Full Text] [Related]
5. 2-Substituted α,β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes.
Bhattarai S; Pippel J; Scaletti E; Idris R; Freundlieb M; Rolshoven G; Renn C; Lee SY; Abdelrahman A; Zimmermann H; El-Tayeb A; Müller CE; Sträter N
J Med Chem; 2020 Mar; 63(6):2941-2957. PubMed ID: 32045236
[TBL] [Abstract][Full Text] [Related]
6. Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors.
Sharif EU; Kalisiak J; Lawson KV; Miles DH; Newcomb E; Lindsey EA; Rosen BR; Debien LPP; Chen A; Zhao X; Young SW; Walker NP; Sträter N; Scaletti ER; Jin L; Xu G; Leleti MR; Powers JP
J Med Chem; 2021 Jan; 64(1):845-860. PubMed ID: 33399453
[TBL] [Abstract][Full Text] [Related]
7. Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017-present).
Nocentini A; Capasso C; Supuran CT
Expert Opin Ther Pat; 2021 Oct; 31(10):867-876. PubMed ID: 33909515
[TBL] [Abstract][Full Text] [Related]
8. Discovery of natural product ellagic acid as a potent CD73 and CD39 dual inhibitor.
Wang Y; Wang C; Zhu Y; Zhang Y; Chen B; Wu Y; Yao J; Miao Z
Bioorg Med Chem Lett; 2021 Feb; 34():127758. PubMed ID: 33359608
[TBL] [Abstract][Full Text] [Related]
9. CD73 promotes proliferation and migration of human cervical cancer cells independent of its enzyme activity.
Gao ZW; Wang HP; Lin F; Wang X; Long M; Zhang HZ; Dong K
BMC Cancer; 2017 Feb; 17(1):135. PubMed ID: 28202050
[TBL] [Abstract][Full Text] [Related]
10. Application of a fluorine strategy in the lead optimization of betulinic acid to the discovery of potent CD73 inhibitors.
Zhang Y; Yang K; Ye S; Tang W; Chang X; Wang Y; Wang C; Wang Y; Wu Y; Miao Z
Steroids; 2022 Dec; 188():109112. PubMed ID: 36150476
[TBL] [Abstract][Full Text] [Related]
11. 4-Substituted-1,2,3-triazolo nucleotide analogues as CD73 inhibitors, their synthesis, in vitro screening, kinetic and in silico studies.
Ghoteimi R; Braka A; Rodriguez C; Cros-Perrial E; Tai Nguyen V; Uttaro JP; Mathé C; Chaloin L; Ménétrier-Caux C; Jordheim LP; Peyrottes S
Bioorg Chem; 2021 Feb; 107():104577. PubMed ID: 33450542
[TBL] [Abstract][Full Text] [Related]
12. CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model.
Tsukui H; Horie H; Koinuma K; Ohzawa H; Sakuma Y; Hosoya Y; Yamaguchi H; Yoshimura K; Lefor AK; Sata N; Kitayama J
BMC Cancer; 2020 May; 20(1):411. PubMed ID: 32397971
[TBL] [Abstract][Full Text] [Related]
13. Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function.
Jin R; Liu L; Xing Y; Meng T; Ma L; Pei J; Cong Y; Zhang X; Ren Z; Wang X; Shen J; Yu K
Mol Cancer Ther; 2020 Nov; 19(11):2340-2352. PubMed ID: 32943546
[TBL] [Abstract][Full Text] [Related]
14. CD73-TNAP crosstalk regulates the hypertrophic response and cardiomyocyte calcification due to α1 adrenoceptor activation.
Gan XT; Taniai S; Zhao G; Huang CX; Velenosi TJ; Xue J; Urquhart BL; Karmazyn M
Mol Cell Biochem; 2014 Sep; 394(1-2):237-46. PubMed ID: 24894822
[TBL] [Abstract][Full Text] [Related]
15. CD73-adenosine: a next-generation target in immuno-oncology.
Allard D; Allard B; Gaudreau PO; Chrobak P; Stagg J
Immunotherapy; 2016 Feb; 8(2):145-63. PubMed ID: 26808918
[TBL] [Abstract][Full Text] [Related]
16. Orally Bioavailable Small-Molecule CD73 Inhibitor (OP-5244) Reverses Immunosuppression through Blockade of Adenosine Production.
Du X; Moore J; Blank BR; Eksterowicz J; Sutimantanapi D; Yuen N; Metzger T; Chan B; Huang T; Chen X; Chen Y; Duong F; Kong W; Chang JH; Sun J; Zavorotinskaya T; Ye Q; Junttila MR; Ndubaku C; Friedman LS; Fantin VR; Sun D
J Med Chem; 2020 Sep; 63(18):10433-10459. PubMed ID: 32865411
[TBL] [Abstract][Full Text] [Related]
17. Generation of Non-Nucleotide CD73 Inhibitors Using a Molecular Docking and 3D-QSAR Approach.
Bhujbal SP; Hah JM
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884548
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of Substituted 5'-Aminoadenosine Derivatives and Evaluation of Their Inhibitory Potential toward CD73.
Ghoteimi R; Nguyen VT; Rahimova R; Grosjean F; Cros-Perrial E; Uttaro JP; Mathé C; Chaloin L; Jordheim LP; Peyrottes S
ChemMedChem; 2019 Aug; 14(15):1431-1443. PubMed ID: 31264794
[TBL] [Abstract][Full Text] [Related]
19. Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays.
Allard B; Cousineau I; Spring K; Stagg J
Methods Enzymol; 2019; 629():269-289. PubMed ID: 31727245
[TBL] [Abstract][Full Text] [Related]
20. Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39.
Jeffrey JL; Lawson KV; Powers JP
J Med Chem; 2020 Nov; 63(22):13444-13465. PubMed ID: 32786396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
